Bristol-Myers Squibb Co


  • Did Accused Bristol-Myers Exec Give Himself Away? Thursday, 2 Aug 2012 | 1:37 PM ET

    The first rule of insider trading: Don’t talk about insider trading—or do a lot of Internet searches about it.

  • Stocks to Watch: SNE, ARO, OMX & More Thursday, 2 Aug 2012 | 1:12 PM ET

    Take a look at some of Thursday's midday movers:

  • Bristol-Myers Executive Charged With Insider Trading Thursday, 2 Aug 2012 | 11:31 AM ET

    FBI agents arrested Robert Ramnarine, a Bristol-Myers Squibb executive, on Thursday, and criminally charged him with insider trading in call options, court papers show.

  • Bristol’s Hep C Drug Blowup May Benefit These Stocks Thursday, 2 Aug 2012 | 10:51 AM ET

    Bristol-Myers Squibb suspended a mid-stage study of its experimental hepatitis C drug BMS-094 due to a serious safety issue — a major blow to the company’s research pipeline that is also likely to rejigger the way Wall Street views other companies’ efforts to develop an all-oral therapy against the viral liver disease.

  • Stocks to Watch: AAPL, CAT, BA & More Wednesday, 25 Jul 2012 | 8:23 AM ET

    Take a look at some of Wednesday's morning movers:

  • Generic competition will be the major headwind that Bristol-Myers Squibb faces this quarter, as its blockbuster drug Plavix — which saw U.S. sales peak at $7 billion last year — went off patent in May.

  • Can Regeneron Continue to Grow?     Monday, 2 Jul 2012 | 2:14 PM ET

    Dr. Leonard Schleifer, Regeneron Pharmaceuticals president & CEO, discusses competition in the pharma sector and upcoming clinical trials. "One of the things that's particularly exciting for a lot of people is our approach to lowering cholesterol," says Schleifer.

  • Bristol Buying Amylin for $7.1 Billion     Monday, 2 Jul 2012 | 2:11 PM ET

    CNBC's Seema Mody discusses the details of the deal between pharma companies Bristol-Myers and Amylin.

  • $7.1 Billion Pharma Deal     Monday, 2 Jul 2012 | 1:11 PM ET

    CNBC's Scott Cohn reports on what the Justice Department calls the biggest health care fraud settlement in U.S. history; and CNBC's Seema Mody reports on the details of Bristol-Myers' plans to buy Amylin.

  • Faber Report: Dish Network Drops AMC     Monday, 2 Jul 2012 | 9:38 AM ET

    CNBC's David Faber reports the Dish Network and AMC contract expired without a new agreement, and a look at the deal between Bristol-Myers and Amylin Pharma.

  • Futures Turn Mixed Ahead of EU Summit Wednesday, 27 Jun 2012 | 8:55 AM ET

    U.S. stock index futures briefly edged higher Wednesday following a better-than-expected durable goods orders report, but quickly erased gains to turn mixed again as investors remained cautious ahead of another EU summit later this week.

  • Barbara Ryan, Deutsche Bank Securities senior pharmaceutical analyst, takes a look at the vital signs of big drug companies and weighs in on what to expect from the Supreme Court's ruling on President Obama's health care overhaul plan.

  • Facebook Trading Inversely to Market     Wednesday, 30 May 2012 | 9:50 AM ET

    The "Squawk on the Street" team discusses the latest action in Facebook, Bristol-Myers and Eli Lilly.

  • Pharma's Rare Disease Strategy     Wednesday, 23 May 2012 | 1:23 PM ET

    Investors have made big bets on drugs like Pfizer's Lipitor for cholesterol, Glaxo's Advair for Asthma, and many more. CNBC's Seema Mody reports rare diseases might be the next hot investment.

  • What's Next For Pharma?     Wednesday, 16 May 2012 | 1:16 PM ET

    Bristol-Myers' top selling blood thinner "Plavix" is going generic, reports CNBC's Seema Mody. Matt Cheslock, Virtu Financial, weighs in on how to trade the pharmaceuticals sector right now.

  • Two Corporate Bribery Investigations: BMY & AVP     Thursday, 26 Apr 2012 | 1:00 PM ET

    CNBC's Eamon Javers reports on Bristol-Meyers receiving a subpoena from the SEC. Also, Avon Group's Vice President Kerry Carr is resigning amid allegations of a bribery in China.

  • GlaxoSmithKline CEO on Earnings     Tuesday, 7 Feb 2012 | 11:15 AM ET

    A breakdown of the drug-maker's Q4 profit after reporting a loss a year earlier, with Andrew Witty, GlaxoSmithKline CEO.

  • Cramer's Specialty Drug Plays in Big Pharma     Tuesday, 24 Jan 2012 | 6:15 PM ET

    Mad Money's Jim Cramer, explains how big drug makers like, Pfizer and Bristol-Myers could pay off big time for investors.

  • Onyx Pharma CEO's 2012 Plan     Tuesday, 10 Jan 2012 | 12:26 PM ET

    Dr. Tony Coles, president & CEO of Onyx Pharmaceuticals, discusses his outlook on pharma in the new year. Biotech stocks were up 7% in 2011. "The emerging markets should be great for us," he adds.

  • Dendreon CEO: Oncology Investments     Tuesday, 10 Jan 2012 | 11:17 AM ET

    Dendreon's revenues for its solo product, Provenge, has more than tripled from a year ago. Insight on the drug's treatment of prostate cancer and an outlook on the healthcare sector, with Mitchell Gold, Dendreon president/CEO.

Most Popular Video

Wednesday, 16 Apr 2014 | 12:00 AM ET

GM unveils new models, hopes for strong sales this year After massive recalls, General Motors is pushing forward with new car models unveiled at the 2014 New York International Auto Show. CNBC's Phil LeBeau explains.

Friday, 11 Apr 2014 | 7:23 AM ET

Former Fed Chairman Ben Bernanke challenges Raghuram Rajan, Reserve Bank of India governor on his views about monetary policies, reports CNBC's Michelle Caruso-Cabrera.

Tuesday, 15 Apr 2014 | 5:40 PM ET

Jonathan Geller, BGR president and editor-in-chief, weighs in on the specifications for Amazon's newly announced 3-D smartphone.